Skip to main content
. 2011 May 16;29(18):2448–2458. doi: 10.1200/JCO.2010.30.3552

Fig 2.

Fig 2.

Loss of nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) during breast cancer progression. Levels of Nuc-pYStat5 as detected by immunofluorescence and quantified by automated quantitative analysis (AQUA) were significantly reduced in invasive ductal carcinoma (IDC; n = 72) and lymph node metastases (LN Met; n = 17) when compared with normal breast tissue (n = 27) and ductal carcinoma in situ (DCIS; n = 14) in progression array cohort III. (*) P = .012; (***) P < .001.